Corrigendum to "The tale of soluble receptors and binding proteins: From bench to bedside" [Cytokine Growth Factor Rev. 18 (2007) 525-33] (DOI:10.1016/j.cytogfr.2007.06.024);The tale of soluble receptors and binding proteins: From bench to bedside

Cytokine and Growth Factor Reviews

Volumn 18, Issue 5-6, 2007, Pages 525-533

  Novick, Daniela ^a   Rubinstein, Menachem ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Cytokine; Interleukin; Ligand affinity chromatography

Indexed keywords

ALPHA INTERFERON RECEPTOR; BETA INTERFERON RECEPTOR; BINDING PROTEIN; BIOLOGICAL MARKER; CELL RECEPTOR; CYTOKINE; GAMMA INTERFERON RECEPTOR; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 6 RECEPTOR; MYELOBLASTIN; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

AFFINITY CHROMATOGRAPHY; ARTICLE; BINDING AFFINITY; BODY FLUID; CELL SURFACE; HUMAN; LIGAND BINDING; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN ISOLATION; PROTEIN STRUCTURE;

EID: 34548134860     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2007.10.001     Document Type: Erratum

References (42)

1. Rubin L.A., Kurman C.C., Fritz M.E., Biddison W.E., Boutin B., Yarchoan R., et al. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135 (1985) 3172-3177
2. Engelmann H., Aderka D., Rubinstein M., Rotman D., and Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 264 (1989) 11974-11980
3. Engelmann H., Novick D., and Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 265 (1990) 1531-1536
4. Novick D., Engelmann H., Wallach D., and Rubinstein M. Soluble cytokine receptors are present in normal human urine. J Exp Med 170 (1989) 1409-1414
5. Novick D., Shulman L.M., Chen L., and Revel M. Enhancement of interleukin 6 cytostatic effect on human breast carcinoma cells by soluble IL-6 receptor from urine and reversion by monoclonal antibody. Cytokine 4 (1992) 6-11
6. Fischer D.G., Tal N., Novick D., Barak S., and Rubinstein M. An antiviral soluble form of the LDL receptor induced by interferon. Science 262 (1993) 250-253
7. Novick D., Cohen B., and Rubinstein M. Soluble interferon-alpha receptor molecules are present in body fluids. FEBS Lett 314 (1992) 445-448
8. Uze G., Lutfalla G., and Gresser I. Genetic transfer of a functional human interferon alpha receptor into mouse cells: cloning and expression of its cDNA. Cell 60 (1990) 225-234
9. Novick D., Cohen B., and Rubinstein M. The human interferon alpha/beta receptor: characterization and molecular cloning. Cell 77 (1994) 391-400
10. Domanski P., Witte M., Kellum M., Rubinstein M., Hackett R., Pitha P., et al. Cloning and expression of a long form of the beta subunit of the interferon alpha beta receptor that is required for signaling. J Biol Chem 270 (1995) 21606-21611
11. Cohen B., Novick D., Barak S., and Rubinstein M. Ligand-induced association of the type I interferon receptor components. Mol Cell Biol 15 (1995) 4208-4214
12. Kim S.H., Cohen B., Novick D., and Rubinstein M. Mammalian type I interferon receptors consists of two subunits: IFNaR1 and IFNaR2. Gene 196 (1997) 279-286
13. Nakamura K., Okamura H., Wada M., Nagata K., and Tamura T. Endotoxin-induced serum factor that stimulates gamma interferon production. Infect Immun 57 (1989) 590-595
14. Ushio S., Namba M., Okura T., Hattori K., Nukada Y., Akita K., et al. Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J Immunol 156 (1996) 4274-4279
15. Novick D., Kim S.H., Fantuzzi G., Reznikov L.L., Dinarello C.A., and Rubinstein M. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 10 (1999) 127-136
16. Kim S.H., Eisenstein M., Reznikov L., Fantuzzi G., Novick D., Rubinstein M., et al. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci USA 97 (2000) 1190-1195
17. Hurgin V., Novick D., and Rubinstein M. The promoter of IL-18 binding protein: activation by an IFN-gamma -induced complex of IFN regulatory factor 1 and CCAAT/enhancer binding protein beta. Proc Natl Acad Sci USA 99 (2002) 16957-16962
18. Novick D., Rubinstein M., Azam T., Rabinkov A., Dinarello C.A., and Kim S.H. Proteinase 3 is an IL-32 binding protein. Proc Natl Acad Sci USA 103 (2006) 3316-3321
19. Kim S.H., Han S.Y., Azam T., Yoon D.Y., and Dinarello C.A. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 22 (2005) 131-142
20. Dziarski R., Platt K.A., Gelius E., Steiner H., and Gupta D. Defect in neutrophil killing and increased susceptibility to infection with nonpathogenic gram-positive bacteria in peptidoglycan recognition protein-S (PGRP-S)-deficient mice. Blood 102 (2003) 689-697
21. Novick D., Eshhar Z., and Rubinstein M. Monoclonal antibodies to human alpha-interferon and their use for affinity chromatography. J Immunol 129 (1982) 2244-2247
22. Novick D., Eshhar Z., Gigi O., Marks Z., Revel M., and Rubinstein M. Affinity chromatography of human fibroblast interferon (IFN-beta 1) by monoclonal antibody columns. J Gen Virol 64 Pt 4 (1983) 905-910
23. Novick D., Eshhar Z., Fischer D.G., Friedlander J., and Rubinstein M. Monoclonal antibodies to human interferon-gamma: production, affinity purification and radioimmunoassay. EMBO J 2 (1983) 1527-1530
24. Novick D., Eshhar Z., Revel M., and Mory Y. Monoclonal antibodies for affinity purification of IL-6/IFN-beta 2 and for neutralization of HGF activity. Hybridoma 8 (1989) 561-567
25. Chernajovsky Y., Mory Y., Chen L., Marks Z., Novick D., Rubinstein M., et al. Efficient constitutive production of human fibroblast interferon by hamster cells transformed with the IFN-beta 1 gene fused to an SV40 early promoter. DNA 3 (1984) 297-308
26. Mory Y., Ben-Barak J., Segev D., Cohen B., Novick D., Fischer D.G., et al. Efficient constitutive production of human IFN-gamma in Chinese hamster ovary cells. DNA 5 (1986) 181-193
27. Novick D., Orchansky P., Revel M., and Rubinstein M. The human interferon-gamma receptor. Purification, characterization, and preparation of antibodies. J Biol Chem 262 (1987) 8483-8487
28. Novick D., Fischer D.G., Reiter Z., Eshhar Z., and Rubinstein M. Monoclonal antibodies to the human interferon-gamma receptor: blocking of the biological activities of interferon-gamma and purification of the receptor. J Interferon Res 9 (1989) 315-328
29. Novick D., Engelmann H., Revel M., Leitner O., and Rubinstein M. Monoclonal antibodies to the soluble human IL-6 receptor: affinity purification, ELISA, and inhibition of ligand binding. Hybridoma 10 (1991) 137-146
30. Novick D., Nabioullin R.R., Ragsdale W., McKenna S., Weiser W., Garone L., et al. The neutralization of type I IFN biologic actions by anti-IFNAR-2 monoclonal antibodies is not entirely due to inhibition of Jak-Stat tyrosine phosphorylation. J Interferon Cytokine Res 20 (2000) 971-982
31. Novick D., Schwartsburd B., Pinkus R., Suissa D., Belzer I., Sthoeger Z., et al. A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine 14 (2001) 334-342
32. De Benedetti F., Massa M., Pignatti P., Albani S., Novick D., and Martini A. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 93 (1994) 2114-2119
33. Toren A., Barak V., Novick D., and Nagler A. Soluble interferon-gamma receptor and interferon-gamma in patients undergoing allogeneic bone marrow transplantation for hematological malignancies. Cytokines Cell Mol Ther 3 (1997) 153-158
34. Toren A., Novick D., Or R., Ackerstein A., Slavin S., and Nagler A. Soluble interleukin-6 receptors in hematology patients undergoing bone marrow transplantation. Transplantation 62 (1996) 138-142
35. Ambrus J.L., Ambrus Jr. J.L., Chadha S., Novick D., Rubinstein M., Gopalkrishnan B., et al. Mechanism(S) of interferon inhibitory activity in blood from patients with AIDS and patients with lupus erythematosus with vasculitis. Res Commun Mol Pathol Pharmacol 96 (1997) 255-265
36. Corbaz A., ten Hove T., Herren S., Graber P., Schwartsburd B., Belzer I., et al. IL-18-binding protein expression by endothelial cells and macrophages is up-regulated during active Crohn's disease. J Immunol 168 (2002) 3608-3616
37. Ludwiczek O., Kaser A., Novick D., Dinarello C.A., Rubinstein M., and Tilg H. Elevated systemic levels of free interleukin-18 (IL-18) in patients with Crohn's disease. Eur Cytokine Netw 16 (2005) 27-33
38. Kaser A., Novick D., Rubinstein M., Siegmund B., Enrich B., Koch R.O., et al. Interferon-alpha induces interleukin-18 binding protein in chronic hepatitis C patients. Clin Exp Immunol 129 (2002) 332-338
39. Ludwiczek O., Kaser A., Novick D., Dinarello C.A., Rubinstein M., Vogel W., et al. Plasma levels of interleukin-18 and interleukin-18 binding protein are elevated in patients with chronic liver disease. J Clin Immunol 22 (2002) 331-337
40. Mazodier K., Marin V., Novick D., Farnarier C., Robitail S., Schleinitz N., et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 106 (2005) 3483-3489
41. Wilchek M., and Miron T. Polymers coupled to agarose as stable and high capacity spacers. Methods Enzymol 34 (1974) 72-76
42. Torigoe K., Ushio S., Okura T., Kobayashi S., Taniai M., Kunikata T., et al. Purification and characterization of the human interleukin-18 receptor. J Biol Chem 272 (1997) 25737-25742